Ureter Cancer - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Ureter Cancer - Pipeline Review, H1 2016', provides an overview of the Ureter Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ureter Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ureter Cancer and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Ureter Cancer - The report reviews pipeline therapeutics for Ureter Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Ureter Cancer therapeutics and enlists all their major and minor projects - The report assesses Ureter Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Ureter Cancer Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Ureter Cancer - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Ureter Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Content 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Ureter Cancer Overview 6 Therapeutics Development 7 Pipeline Products for Ureter Cancer - Overview 7 Pipeline Products for Ureter Cancer - Comparative Analysis 8 Ureter Cancer - Therapeutics under Development by Companies 9 Ureter Cancer - Therapeutics under Investigation by Universities/Institutes 10 Ureter Cancer - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Ureter Cancer - Products under Development by Companies 14 Ureter Cancer - Products under Investigation by Universities/Institutes 15 Ureter Cancer - Companies Involved in Therapeutics Development 16 Altor BioScience Corporation 16 Eisai Co., Ltd. 17 Exelixis, Inc. 18 Merck & Co., Inc. 19 Ureter Cancer - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 ALT-801 - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 cabozantinib s-malate - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 eribulin mesylate - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 pembrolizumab - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 PGV-001 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Ureter Cancer - Recent Pipeline Updates 55 Appendix 97 Methodology 97 Coverage 97 Secondary Research 97 Primary Research 97 Expert Panel Validation 97 Contact Us 97 Disclaimer 98
List of Tables
Number of Products under Development for Ureter Cancer, H1 2016 7 Number of Products under Development for Ureter Cancer - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Number of Products under Investigation by Universities/Institutes, H1 2016 10 Comparative Analysis by Late Stage Development, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 12 Comparative Analysis by Early Stage Development, H1 2016 13 Products under Development by Companies, H1 2016 14 Products under Investigation by Universities/Institutes, H1 2016 15 Ureter Cancer - Pipeline by Altor BioScience Corporation, H1 2016 16 Ureter Cancer - Pipeline by Eisai Co., Ltd., H1 2016 17 Ureter Cancer - Pipeline by Exelixis, Inc., H1 2016 18 Ureter Cancer - Pipeline by Merck & Co., Inc., H1 2016 19 Assessment by Monotherapy Products, H1 2016 20 Number of Products by Stage and Target, H1 2016 22 Number of Products by Stage and Mechanism of Action, H1 2016 24 Number of Products by Stage and Route of Administration, H1 2016 26 Number of Products by Stage and Molecule Type, H1 2016 28 Ureter Cancer Therapeutics - Recent Pipeline Updates, H1 2016 55
List of Figures
Number of Products under Development for Ureter Cancer, H1 2016 7 Number of Products under Development for Ureter Cancer - Comparative Analysis, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Assessment by Monotherapy Products, H1 2016 20 Number of Products by Top 10 Targets, H1 2016 21 Number of Products by Stage and Top 10 Targets, H1 2016 21 Number of Products by Top 10 Mechanism of Actions, H1 2016 23 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 23 Number of Products by Routes of Administration, H1 2016 25 Number of Products by Stage and Routes of Administration, H1 2016 25 Number of Products by Molecule Types, H1 2016 27 Number of Products by Stage and Molecule Types, H1 2016 27
Global outsourced customer care services market is projected to reach USD 84.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Swelling need for interaction through non-voice channels is estimated to boost global demand over tRead More...
Global contact lenses market size is estimated to reach USD 12.5 billion by 2020, according to a new industry report by Radiant Insights, Inc. Growing number of ophthalmic disorder observed in global population especially children is likely to driveRead More...
Global fingerprint access control systems market size is estimated to reach USD 4.4 billion by 2022, as per a new research report by Radiant Insights, Inc. Growing safety and security concerns of individual as well as organization is projected to driRead More...
Global lignin market size is expected to exceed USD 6 billion by 2022, growing at 4.9% from 2015 to 2022. Rising demand for animal feed and potential as a feedstock substitute to crude oil are expected to drive lignin market demand over the forecastRead More...
Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expectedRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.